Genome-wide alterations in CpG island methylation induced by arsenite
Keywords:
DNA, CpG islands, methylation, arsenic, epigenetic silencing, keratinocytesAbstract
Aberrant methylation of tumour suppressor CpG islands, resulting in epigenetic gene silencing, is common in human cancer. However, the mechanism responsible for inducing gene silencing remains unclear. Epidemiologic data have confirmed that the human carcinogen arsenic is associated with epigenetic silencing in several tumour-types. In this study, we set out to investigate the role exposure to arsenic plays in inducing CpG island methylation. To test the effects of the USA Environmental Protection Agency’s drinking water arsenic limits (10 ppb), two clonal populations of immortalized human keratinocytes were treated with this level of arsenic, and methylation at CpG islands was compared to pooled, untreated keratinocytes using a 12K genome-wide CpG microarray. Islands with at least a 1.5-fold increase or decrease in methylation were examined. Comparing arrays from duplicate treated, clonal populations, a global decrease in methylation was seen, that involved more than 3000 CpG island loci, with a concomitant increase in methylation at over 500 CpG loci. Between arrays, the specific loci that exceeded the methylation change cutoff had > 99% concordance, demonstrating both reproducibility and specificity. Consistent with alterations from human tumours, this pattern of globally decreased CpG island methylation and local CpG island hypermethylation suggests that arsenic contributes to epigenetic alterations in human cancer.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.